
Memphis—Switches within rather than between classes of glaucoma medications are less common but appropriate when likely to produce an improvement in efficacy, adverse effects, or compliance, said Peter Andreas Netland, MD, PhD, Siegal Professor of Ophthalmology, University of Tennessee Health Science Center, Memphis.